Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis (ULTRA)
Sponsor: Changhai Hospital
A PHASE4 clinical study on Infliximab and Rheumatoid Arthritis, this trial is ongoing. The trial is conducted by Changhai Hospital and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
-
Dec 2018 — Jul 2020 [monthly]
Unknown Status PHASE4
▶ Show 4 earlier versions
-
Aug 2018 — Dec 2018 [monthly]
Unknown Status PHASE4
-
Jul 2018 — Aug 2018 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jul 2018 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Changhai Hospital
- First Affiliated Hospital of Wenzhou Medical University
- First Hospital of China Medical University
- First People's Hospital of Foshan
- Peking Union Medical College Hospital
- Shanghai Changzheng Hospital
- Shenzhen People's Hospital
- West China Hospital
For direct contact, visit the study record on ClinicalTrials.gov .